Research programme: small molecule protease inhibitors - Biovitrum

Drug Profile

Research programme: small molecule protease inhibitors - Biovitrum

Latest Information Update: 08 Jun 2007

Price : $50

At a glance

  • Originator Biovitrum
  • Class Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 13 Nov 2006 This programme is still in active development with Biovitrum
  • 22 Aug 2005 Arexis has been acquired by Biovitrum
  • 15 Aug 2005 Preclinical trials in Atopic dermatitis in Sweden (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top